WAL 2014 FU (Talsaclidine): A preferentially neuron Activating muscarinic agonist for the treatment of Alzheimer's disease

Drug Development Research

Volumn 40, Issue 2, 1997, Pages 144-157

  Ensinger, Helmut A ^b   Bechtel, Wolf Dieter ^a   Birke, Franz W ^a   Mendla, Klaus D ^a   Mierau, Joachim ^a   Speck, Georg ^a   Tröger, Wolfgang ^a  

^a Dept Pharmacokin and Drug Metab ^*

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Alzheimer's disease; Muscarinic agonist; Talsaclidine; WAL 2014 FU

Indexed keywords

2 ETHYL 8 METHYL 2,8 DIAZASPIRO[4.5]DECANE 1,3 DIONE; [4 [(3 CHLOROPHENYL)CARBAMOYLOXY] 2 BUTYNYL]TRIMETHYLAMMONIUM; ACETYLCHOLINESTERASE; ACETYLGLUCOSAMINIDASE; AMINE OXIDASE (FLAVIN CONTAINING); ARECOLINE; ATROPINE; CARBACHOL; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC RECEPTOR; OXOTREMORINE; RECEPTOR SUBTYPE; TALSACLIDINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; BLOOD BRAIN BARRIER; BRAIN; CHO CELL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG RECEPTOR BINDING; GUINEA PIG; HEART; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; RECEPTOR AFFINITY;

EID: 0030916650     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199702)40:2<144::AID-DDR5>3.0.CO;2-L     Document Type: Article

References (59)

1. Adamus WS, Leonard JP, Tröger W (1995): Phase I clinical trials with WAL 2014 FU, a new muscarinic agonist for the treatment of Alzheimer's disease. Life Sci 56:883-890.
2. Bartus RT, Dean RL III, Beer B, Lippa AS (1982): The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408-417.
3. Bartus RT, Dean RL III, Beer B, Lippa AS (1984): Cholinergic precursor therapy for geriatric cognition: Its past, its present, and a question of its future. In Ordy JM, Harman D, Alsin-Slater R (eds): Nutrition in Gerontology. New York: Raven Press, pp 191-225.
4. Baxter GT, Young ML, Miller DL, Owicki JC (1994): Using microphysiometry to study the pharmacology of exogenously expressed m1 and m3 muscarinic receptors. Life Sci 55:573-583.
5. Berridge MJ, Downes P, Hanley MR (1982): Lithium amplifies agonist-dependent phosphatidyl-inositol responses in brain and salivary glands. Biochem J 206:587-595.
6. Billard W, Ruperto V, Crosby G, Iorio LC, Barnett A (1984): Characterization of the binding of 3H-SCH 23390, a selective D1-receptor antagonist ligand in rat striatum. Life Sci 35:1885-1893.
7. Birke FW, Weber KH (1988): Specific and high affinity binding of WEB 2086 to human platelet PAF receptors. Clin Exp Pharmacol Physiol 15(Suppl 13), 2 Abstr.
8. Buckley NJ, Bonner TI, Buckley CM, Brann MR (1989): Antagonist binding properties for five cloned muscarinic receptors expression in CHO-K1 cells. Mol Pharmacol 22:469-479.
9. Bylund DB, Snyder SH (1976): Beta adrenergic receptor binding in membrane preparations from mammalian brain. Mol Pharmacol 12:568-580.
10. 3H]mepyramine binding of brain membranes. J Neurochem 32:1653-1663.
11. 3H]Leukotriene B4 binding to the guinea pig spleen: A rich tissue source for a high affinity leukotriene B4 receptor site. J Pharmacol Exp Ther 236:126-132.
12. Cheng YC, Prusoff WH (1973): Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50% inhibition of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
13. 3H]cis methyldioxolane in different tissues. Naunyn-Schmiedebergs Arch Pharmacol 335:372-377.
14. Creese I, Burt DR, Snyder SH (1975): Dopamine receptor binding: Differentiation of agonist and antagonist states with 3H-Dopamine and 3H-Haloperidol. Life Sci 17:993-1002.
15. Drachman DA, Leqvitt J (1974): Human memory and the cholinergic system. Arch Neurol 30:113-121.
16. Daly JW, Padgett W, Shamin MT (1985): Xanthines: Potent water soluble antagonists for A1- and A2-adenosine receptors. J Med Chem 28:487-492.
17. 3H]Mr 2034 labels a high affinity opioid kappa receptor not accessible to naloxazone Eur J Pharmacol 89:143-147.
18. Ensinger HA, Doods HN, Immel-Sehr AR, Kulm FJ, Lambrecht G, Mendla KD, Müller RE Mutschler E, Sagrada A, Walther G, Hammer R (1993): WAL 2014 - A muscarinic agonist with preferential neuron-stimulating properties. Life Sci 52:473-180.
19. Farber SA, Nitsch RM Schulz JG, Wurtman RJ (1995): Regulated secretion of b-amyloid precursor protein in rat brain. J Neurosci 15:7442-7451.
20. Francis PT, Palmer AM, Sims NR, Bowen DM, Davison AN, Esiri MM, Neary D, Snowden JS, Wilcock GK (1985): Neurochemical studies of early onset Alzheimer's disease: Possible influence on treatment. N Engl J Med 313:7-11.
21. Freedman SB, Harley EA, Iversen LL (1988): Relative affinities of drugs acting at cholinoceptors in displacing agonist and antagonist radioligands: the NMS/Oxo-M ratio as an index of efficacy at cortical muscarinic receptors. Br J Pharmacol 93:437-145.
22. Freedman SB, Dawson GR, Iversen LL, Baker R, Hargreaves RJ (1993): The design of novel muscarinic partial agonists that have functional selectivity in pharmacological preparations in vitro and reduced side-effect profile in vivo. Life Sci 50:489-495.
23. 3H]tiotidine to histamine H2 receptors in guinea pig cerebral cortex. Nature 304:65-67.
24. Gauthier S, Gauthier L (1991): Status of THA as therapy for Alzheimer's disease. In Becker R. Giacobini E (eds): Cholinergic Basis for Alzheimer Therapy. Boston: Birkhäuser.
25. 3H]GABA binding. Eur J Pharmacol 75:83-92.
26. Gonzales RA, Crews FT (1984): Characterization of the cholinergic stimulation of phosphoinositide hydrolysis of rat brain. J Neurosci 4:3120-3127.
27. Gray EG, Whittler VP (1962): The isolation of nerve endings from brain: An electron-microscopic study of cell fragments derived by homogenisation and centrifugation. J Anat 96:79-88.
28. Greenberg DA, U'Pritchard DC, Snyder SH (1976): Alpha-Noradrenergic receptor binding in mammalian brain: Differential labelling of agonist and antagonist states. Life Sci 19:69-76.
29. 3H-Prazosin to rat brain alpha adrenergic receptors. Eur J Pharmacol 55:323-326.
30. Gutkind JS, Novotny EA, Brann MR, Robbins KC (1991): Muscarinic acetylcholine receptor subtypes as agonist-dependent oncogenes. Proc Natl Acad Sci USA 88:4703-4707.
31. Hammer R, Berrie CP, Birdsall NJM, Burgen ASV, Hulme EC (1980): Pirenzepine distinguishes between different subclasses of muscarinic receptors. Nature 283:90-92.
32. Hammer R, Giraldo E, Schiavi GB, Monferini E, Ladinsky H (1986): Binding profile of a novel cardioselective muscarine receptor antagonist, AF-DX 116, to membranes of peripheral tissues and brain in the rat. Life Sci 38:1653-1662.
33. Heinzel G, Woloszczak R, Thomann P (1993): TOPFIT, Version 2.0, Pharmacokinetic and Pharmacodynamic Data Analysis System. Stuttgart: Gustav Fischer Verlag.
34. 3H]mepyramine to histamine H1 receptors in guinea pig brain. J Neurochem 31:997-1004.
35. Horn AS, Coyle CT, Snyder SH (1971): Catecholamine uptake by synaptosomes from rat brain. Structure-activity relationships of drugs with differential effects on dopamine and norepinephrine neurons. Mol Pharmacol 7:66-80.
36. Jones SVP, Choi OH, Beaven MA (1991): Carbachol induces secretion in a mast cell line (RBL-2H3) transfected with the M1 muscarinic receptor gene. FEBS Lett 289:47-50.
37. Kumar V, Calache M (1991): Treatment of Alzheimer's disease with cholinergic drugs. Int J Clin Pharmacol Ther Toxicol 29:23-37.
38. 3H]Nicotine to a single class of high affinity sites in rat brain membranes. Mol Pharmacol 29:448-454.
39. Little A, Levy R, Chuqui-Kidd P, Hand D (1985): A double-blind, placebo controlled trial of high dose lecithin in Alzheimer's disease. J Neurol Neurosurg Psychiatry 48:736-742.
40. Mendla KD, Jones SVP, Arndts D, Ensinger HA, Brann MR (1993): Human M1 receptor-transfected RBL cells: A novel test system for the characterization of muscarinic agonists. Life Sci 52:571.
41. 3H-diazepam binding tobenzodiazepine receptors in rat cerebral cortex. Life Sci 20:2101-2110.
42. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH (1992): Release of Alzheimer Amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258:304-307.
43. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH (1993) Alzheimer Amyloid β-protein precursor processing is regulated by Neurotransmission. Sixth Congress of the International Psychogeriatric Ass. Berlin, Sept 5-10, Abstract Book p 80.
44. Palacios JM, Spiegel R (1986): Muscarinic cholinergic agonists: Pharmacological and clinical perspectives. Prog Brain Res 70:485-498.
45. Perry EK, Tomlinson BE, Blessed G, Bergman K, Gibson PH, Perry RH (1978): Correlations of cholinergic abnormalities with senile plaques and mental test scores in senile dementia BMJ 2:1457-1459.
46. Peroutka SJ, Lebovitz RM, Snyder SH (1979): Serotonin receptor binding sites affected differentially by guanine nucleotides. Mol Pharmacol 16:700-708.
47. Peroutka SJ (1986): Pharmacological differentiation and characterisation of 5-HT1A, 5-HT1B and 5-HT1C binding sites in rat frontal cortex. J Neurochem 47:52-.540.
48. Peters BH, Levin HS(1979): Effects of physostigmine and lecithin on memory in Alzheimer's disease. Ann Neurol 6:219-221.
49. Rainbow TC, Parsons B, Wolfe BB (1984): Quantitative autoradiography of β1- and β2-adrenergic receptors in rat brain. Proc Natl Acad Sci USA 81:1585-1589.
50. 3H]labelled MK 801 binding to the excitatory amino acid receptor complex from rat brain is enhanced by glycine. Proc Natl Acad Sci USA 84:7744-7748.
51. Roszkowsky AP. (1961) An unusual type of sympathetic ganglionic stimulant. J Pharmacol Exp Ther 132:156-170.
52. Schittkowski, K (1994): Parameter estimation in systems of nonlinear equations. Numer Math 68:129-142.
53. Spiegel R (1991): Cholinergic drugs affective disorders and dementia: problems of clinical research. Acta Psychiatr Scand Suppl 366:66-69.
54. Sullivan EV, Shedlock KJ, Corkin S, Growden JH (1982): Physostigmine and lecithin in Alzheimer's disease. In Corkin S, Davis KL, Growden JH, Usdin E, Wurtman RJ (eds): Alzheimer's Disease: A Report of Progress. Aging. Vol. 19. New York: Plenum Press, pp 361-367.
55. Thai LJ (1991): Physostigmine in Alzheimer's disease. In Becker R, Giacobini E (eds): Cholinergic Basis for Alzheimer Therapy. Boston: Birkhäuser.
56. Thiry L. (1964): Sitzungsberichte Akad Wien, Mathem-Naturwiss Klin 1:43-44.
57. Van Nostrand WE, Wagner SL, Shankle WR, Farrow JS, Dick M, Rozemuller JM, Kuiper MA, Wolters EC, Zimmerman J, Cotman CW, Cunningham DD (1992): Decreased levels of soluble amyloid β-protein precursor in cerebrospinal fluid of live Alzheimer's disease patients. Proc Natl Acad Sci USA 89:2551-2555.
58. 3H]pirenzepine in the rat provide evidence for distinct M1 and M2 muscarinic receptor subtypes. Life Sci 32:3001-3011.
59. Yoneda Y, Ogita K (1989): Abolition of the NMDA-mediated response by a specific glycine antagonist, 6,7-dichloro quinoxaline-2,3-dione (DCQX). Biochem Biophys Res Commun 164:841-849.